Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8209110 | Applied Radiation and Isotopes | 2016 | 6 Pages |
Abstract
This study aimed at the preparation and evaluation of 177Lu-CHX-Aâ²â²-DTPA-Bevacizumab for targeting VEGF over-expressing cancers. Bevacizumab conjugated to p-NCS-Bn-CHX-Aâ²â²-DTPA was radiolabeled with 177Lu. The radioimmunoconjugate characterized by SE-HPLC exhibited radiochemical purity of 98.0±0.6%. In vitro stability was retained upto 4 days at 37 °C. In vitro cell binding studies showed good uptake by VEGF expressing U937 tumor cells. Biodistribution studies in melanoma model showed significant uptake and retention of 177Lu-CHX-Aâ²â²-DTPA-Bevacizumab in tumor with reduction in uptake in presence of cold Bevacizumab confirming its specificity to VEGF.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Mythili Kameswaran, Usha Pandey, Naresh Gamre, K.V. Vimalnath, Haladhar Dev Sarma, Ashutosh Dash,